ATE498408T1 - Gnrh-agonistische kombinationsmittel - Google Patents

Gnrh-agonistische kombinationsmittel

Info

Publication number: ATE498408T1
Authority: AT; Austria
Prior art keywords: drugs; gnrh; gnrh agonist; qol; preventive
Prior art date: 2001-08-10

Application number

AT02758814T

Other languages

English (en)

Inventor

Shuichi Furuya

Masami Kusaka

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-10

Filing date

2002-08-08

Publication date

2011-03-15

2002-08-08 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE498408T1 publication Critical patent/ATE498408T1/de

Links

101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 title 1
102100024028 Progonadoliberin-1 Human genes 0.000 title 1
230000001270 agonistic effect Effects 0.000 title 1
239000003814 drug Substances 0.000 abstract 4
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 3
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 3
239000000556 agonist Substances 0.000 abstract 3
229940079593 drug Drugs 0.000 abstract 3
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
230000003449 preventive effect Effects 0.000 abstract 2
230000001225 therapeutic effect Effects 0.000 abstract 2
102000019034 Chemokines Human genes 0.000 abstract 1
108010012236 Chemokines Proteins 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 1
101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 abstract 1
102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 abstract 1
229940127394 Sex Hormone Synthesis Inhibitors Drugs 0.000 abstract 1
230000004097 bone metabolism Effects 0.000 abstract 1
239000002308 endothelin receptor antagonist Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
238000009169 immunotherapy Methods 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000000849 selective androgen receptor modulator Substances 0.000 abstract 1
239000000333 selective estrogen receptor modulator Substances 0.000 abstract 1
229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract 1
239000005483 tyrosine kinase inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Pregnancy & Childbirth (AREA)
Psychiatry (AREA)
Oncology (AREA)
Gynecology & Obstetrics (AREA)
Obesity (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Ultra Sonic Daignosis Equipment (AREA)

AT02758814T 2001-08-10 2002-08-08 Gnrh-agonistische kombinationsmittel ATE498408T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001244616		2001-08-10
PCT/JP2002/008130 WO2003015820A1 (en)	2001-08-10	2002-08-08	GnRH AGONIST COMBINATION DRUGS

Publications (1)

Publication Number	Publication Date
ATE498408T1 true ATE498408T1 (de)	2011-03-15

Family

ID=19074519

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02758814T ATE498408T1 (de)	2001-08-10	2002-08-08	Gnrh-agonistische kombinationsmittel

Country Status (7)

Country	Link
US (3)	US20050215528A1 (de)
EP (1)	EP1424080B1 (de)
JP (1)	JP2003137814A (de)
AT (1)	ATE498408T1 (de)
CA (1)	CA2458452C (de)
DE (1)	DE60239207D1 (de)
WO (1)	WO2003015820A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE498408T1 (de) *	2001-08-10	2011-03-15	Takeda Pharmaceutical	Gnrh-agonistische kombinationsmittel
US8853266B2 (en)	2001-12-06	2014-10-07	University Of Tennessee Research Foundation	Selective androgen receptor modulators for treating diabetes
KR101041767B1 (ko) *	2002-06-25	2011-06-17	다케다 야쿠힌 고교 가부시키가이샤	서방성 조성물의 제조 방법
PL375042A1 (en)	2002-08-12	2005-11-14	Takeda Pharmaceutical Company Limited	Fused benzene derivative and use
GB0219660D0 (en)	2002-08-23	2002-10-02	Astrazeneca Ab	Therapeutic use
GB0307777D0 (en)	2003-04-04	2003-05-07	Medical Res Council	Conjugate compounds
WO2004100991A1 (en) *	2003-05-15	2004-11-25	Universite Catholique De Louvain	Use of endothelin-1 antagonists for improving cancer therapy
JP2004344035A (ja) *	2003-05-21	2004-12-09	Kureha Chem Ind Co Ltd	担子菌の乾燥方法
GB0320806D0 (en) *	2003-09-05	2003-10-08	Astrazeneca Ab	Therapeutic treatment
US20070191311A1 (en) *	2004-01-30	2007-08-16	Shuichiro Kakimoto	P2x receptor inhibitor
GB0403744D0 (en)	2004-02-20	2004-03-24	Astrazeneca Ab	Chemical process
US8642079B2 (en)	2004-02-23	2014-02-04	Hormos Medical Corporation	Solid formulations of ospemifene
MXPA06012758A (es)	2004-05-04	2007-01-16	Hormos Medical Ltd	Novedosas formulaciones orales de ospemifeno.
CN102976973B (zh) *	2004-06-07	2015-10-21	田纳西大学研究基金会	选择性雄激素受体调节剂及其使用方法
US9889110B2 (en)	2004-06-07	2018-02-13	University Of Tennessee Research Foundation	Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en)	2004-06-07	2018-02-06	University Of Tennessee Research Foundation	Selective androgen receptor modulator and methods of use thereof
US20080171736A1 (en) *	2004-12-23	2008-07-17	Gregory Christopher W	Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
AU2006287767B2 (en) *	2005-09-07	2010-05-13	Merck Serono Sa	IKK inhibitors for the treatment of endometriosis
NZ570381A (en) *	2006-02-09	2011-02-25	Daiichi Sankyo Co Ltd	Anti-cancer pharmaceutical composition
WO2008099060A2 (en) *	2007-02-14	2008-08-21	Hormos Medical Ltd	Methods for the preparation of fispemifene from ospemifene
PL2121553T3 (pl) *	2007-02-14	2012-11-30	Hormos Medical Ltd	Sposób wytwarzania cennych terapeutycznie pochodnych trifenylobutenu
US7968603B2 (en)	2007-09-11	2011-06-28	University Of Tennessee Research Foundation	Solid forms of selective androgen receptor modulators
KR20100061481A (ko) *	2007-09-11	2010-06-07	몬도바이오테크 래보래토리즈 아게	치료제로서의 미니가스트린
JP5937297B2 (ja) *	2010-03-01	2016-06-22	キヤノンアネルバ株式会社	金属窒化膜、該金属窒化膜を用いた半導体装置、および半導体装置の製造方法
EA026675B1 (ru)	2010-06-16	2017-05-31	Эндорешерш, Инк.	Способы лечения или предотвращения эстрогензависимых заболеваний
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
LT2872482T (lt)	2012-07-13	2020-12-28	Oncternal Therapeutics, Inc.	Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US9321712B2 (en)	2012-10-19	2016-04-26	Fermion Oy	Process for the preparation of ospemifene
EP3803866A4 (de)	2018-05-24	2022-03-16	Nureva Inc.	Verfahren, vorrichtung und computerlesbare medien zur verwaltung halbkonstanter (persistenter) schallquellen in mikrofonaufnahme-/-fokuszonen
KR20260007295A (ko)	2018-05-24	2026-01-13	셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨	거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
MX2020012459A (es)	2018-05-24	2021-04-28	Celanese Eva Performance Polymers Llc	Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
BR112023022439A2 (pt)	2021-04-26	2023-12-26	Celanese Eva Performance Polymers Llc	Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
US11977085B1 (en)	2023-09-05	2024-05-07	Elan Ehrlich	Date rape drug detection device and method of using same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2438350C3 (de) *	1974-08-09	1979-06-13	Hoechst Ag, 6000 Frankfurt	Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
FR2465486A1 (fr) *	1979-09-21	1981-03-27	Roussel Uclaf	Nouvelle application utilisant la lh-rh ou des agonistes
IE58836B1 (en) *	1984-08-02	1993-11-17	Labrie Fernand	Pharmaceutical composition for combination therapy of hormone dependent cancers
DE19604231A1 (de) *	1996-01-29	1997-07-31	Schering Ag	Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
AU2407997A (en) *	1996-04-30	1997-11-19	Takeda Chemical Industries Ltd.	Combined use of gnrh agonist and antagonist
US20020019346A1 (en) *	1997-05-21	2002-02-14	Children's Medical Center Corporation	Treatment of prostate cancer by inhibiting lyn tyrosine kinase
CA2299471C (en) *	1997-08-15	2007-12-18	Cephalon Inc.	Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
TR200002059T2 (tr) *	1998-01-16	2001-01-22	Takeda Chemical Industries, Ltd.	Devamlı salınan bileşim, üretim yöntemi ve kullanımı.
EP1073640B1 (de) *	1998-04-23	2005-04-13	Takeda Pharmaceutical Company Limited	Naphthalene derivate ,ihre herstellung und verwendung
DE19833786A1 (de) *	1998-07-18	2000-01-20	Schering Ag	Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ID28791A (id) *	1998-08-07	2001-07-05	Endorech Inc	PENGHAMBATAN DEHIDROGENASE HIDROKSISTEROID 3α TIPE 3
US20040127470A1 (en) *	1998-12-23	2004-07-01	Pharmacia Corporation	Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
AU7950100A (en) *	1999-10-22	2001-05-08	Takeda Chemical Industries Ltd.	1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof
JP4520012B2 (ja) *	1999-10-22	2010-08-04	武田薬品工業株式会社	１−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類
GB0008368D0 (en) *	2000-04-06	2000-05-24	Astrazeneca Ab	Combination product
PE20011178A1 (es) *	2000-04-07	2001-11-19	Takeda Chemical Industries Ltd	Compuestos heterociclicos y su produccion
US20030176360A1 (en) *	2000-07-05	2003-09-18	Yasutaka Igari	Medicinal preparations for treating sex hormone-dependent diseases
JP4121268B2 (ja) *	2000-11-20	2008-07-23	武田薬品工業株式会社	イミダゾール誘導体、その製造法および用途
JP4160295B2 (ja) *	2000-12-08	2008-10-01	武田薬品工業株式会社	３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
JP2002241268A (ja) *	2000-12-11	2002-08-28	Takeda Chem Ind Ltd	水溶解性が改善された医薬組成物
EP1382350A4 (de) *	2001-04-25	2006-01-04	Takeda Pharmaceutical	Mittel zur prophylaxe vor postoperativem wiederauftreten von prämenopausalem brustkrebs
US6872715B2 (en) *	2001-08-06	2005-03-29	Kosan Biosciences, Inc.	Benzoquinone ansamycins
ATE498408T1 (de) *	2001-08-10	2011-03-15	Takeda Pharmaceutical	Gnrh-agonistische kombinationsmittel
US7812044B2 (en) *	2001-11-13	2010-10-12	Takeda Pharmaceutical Company Limited	Anticancer agents

2002
- 2002-08-08 AT AT02758814T patent/ATE498408T1/de not_active IP Right Cessation
- 2002-08-08 EP EP02758814A patent/EP1424080B1/de not_active Expired - Lifetime
- 2002-08-08 JP JP2002231922A patent/JP2003137814A/ja active Pending
- 2002-08-08 CA CA2458452A patent/CA2458452C/en not_active Expired - Fee Related
- 2002-08-08 DE DE60239207T patent/DE60239207D1/de not_active Expired - Lifetime
- 2002-08-08 US US10/486,095 patent/US20050215528A1/en not_active Abandoned
- 2002-08-08 WO PCT/JP2002/008130 patent/WO2003015820A1/ja not_active Ceased
2007
- 2007-03-27 US US11/727,549 patent/US20070179097A1/en not_active Abandoned
2010
- 2010-05-07 US US12/662,866 patent/US20100286063A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20070179097A1 (en)	2007-08-02
US20050215528A1 (en)	2005-09-29
EP1424080B1 (de)	2011-02-16
CA2458452C (en)	2011-04-19
US20100286063A1 (en)	2010-11-11
WO2003015820A1 (en)	2003-02-27
CA2458452A1 (en)	2003-02-27
DE60239207D1 (de)	2011-03-31
EP1424080A4 (de)	2004-09-01
JP2003137814A (ja)	2003-05-14
EP1424080A1 (de)	2004-06-02

Legal Events

Date	Code	Title	Description
2011-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE498408T1 (de)	2011-03-15	Gnrh-agonistische kombinationsmittel
Dorai et al.	2000	Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein
BRPI0408247A (pt)	2006-03-01	usos de antagonistas e agonistas de il-23 e reagentes relacionados
DE602005013490D1 (de)	2009-05-07	Missbrauchsichere transdermale abgabevorrichtung für opioide, enthaltend opioidantagonist in form von mikrokügelchen
TW200517126A (en)	2005-06-01	Mesothelioma therapeutic agent
AP2004002982A0 (en)	2004-03-31	Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
DK1379224T3 (da)	2009-11-09	Guanylat-cyclase receptor-agonister til behandling af vævsinflammation og carciogenese
ATE469897T1 (de)	2010-06-15	Indazolcarbonsäureamidverbindungen
MA32397B1 (fr)	2011-06-01	Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
GEP20063741B (en)	2006-02-10	Nonaryl-Heterocyclic NMDA/NR2B Antagonists
ECSP034772A (es)	2003-10-28	Antagonistas de mch y su uso en el tratamiento de obesidad
MX2009003469A (es)	2009-05-28	Uso de farmacos que inducen hipotermia para el tratamiento de isquemia.
TW200730168A (en)	2007-08-16	Combination of an H3 antagonist/inverse agonist and an appetite suppressant
BRPI0409910A (pt)	2006-04-25	métodos para o tratamento de doenças relacionadas com interleucina-6
ATE535514T1 (de)	2011-12-15	Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
UA93209C2 (ru)	2011-01-25	Комбинация снотворного агента продолжительного действия эпливансерина и снотворного агента короткого действия золпидема
EA200501019A1 (ru)	2006-06-30	Противораковое лекарственное средство, фармацевтическая композиция и способ ингибирования размера опухоли (варианты) на его основе
TW200531679A (en)	2005-10-01	Methods of modulating cytokine activity; related reagents
IL162862A (en)	2011-04-28	Short-acting sedative hypnotic agents for anesthesia and sedation and pharmaceutical compositions containing them
MXPA05012358A (es)	2006-02-02	Combinacion farmaceutica que comprende modafinilo y otra droga.
UY28007A1 (es)	2004-04-30	Tratamiento terapeutico
MXPA05013478A (es)	2006-03-09	Combinaciones terapeuticas.
EA200801369A1 (ru)	2009-02-27	Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
MXPA05009135A (es)	2005-10-20	Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
WO2004000219A3 (en)	2004-03-11	Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof